Published: Mar-2021 | Format: PDF | Market Research Store | Number of pages: 120 | Code: MRS - 828547
According to the report published by Market Research Store, global demand for the acute myeloid leukemia (AML) therapeutics market was estimated at approximately USD 550 Million in 2019 and is anticipated to generate revenue of around USD 1,140 Million by end of 2026, growing at a CAGR of around 11% between 2020 and 2026.
Leukemia is a broad term for a variety of cancers that involve the bone marrow and white blood cells (WBC). Leukemia is described by a sudden rise in the number of irregular blood cells, known as blasts, resulting in a reduction in the number of stable, completely modified blood cells, resulting in the usual signs of bleeding, anemia, and a high risk of infection. Leukemia may develop in either the myeloid or lymphoid stem cell lines, depending on how genetic and epigenetic mutations affect the migration of pluripotent stem cells to the different lines of mature cells that then enter the bloodstream. Acute myeloid leukemia (AML) is a kind of blood cancer that generally affects white blood cells (WBCs), but may also affect other blood-forming cells. In AML, irregular WBCs are generated rapidly, gets accumulated in the bone marrow, and interfere in the development of regular blood cells.
As a result of the increasing incidences of acute myeloid leukemia (AML) and its relapse cases around the world, the market is expected to rise at a healthy rate over the projected period. The surging need and demand for advanced therapeutics also foster market growth. Genetic anomalies, toxic habits, prolonged exposure to dangerous substances such as benzene, and radiation sensitivity have all been linked to an increase in the use of AML therapeutics. Furthermore, the demand is projected to escalate propel owing to the geriatric population grows and unmet healthcare needs grow. Present medication treatments for acute myeloid leukemia are projected to be restricted, resulting in a need for more and more efficient therapies, which would propel the industry further. However, the high cost of the therapeutic procedure, as well as safety issues, is projected to hamper the market growth in the coming years. Furthermore, continuing research has resulted in the development of more effective cancer treatments, which presents lucrative prospects for key industry players.
The global acute myeloid leukemia (AML) therapeutics market is divided based on treatment type, end-user, and region. The end-user segment is bifurcated into clinics, hospitals, oncology centers, retails drug stores, ambulatory care centers, and others. The treatment type segment is categorized into targeted therapy, chemotherapy, radiation therapy, stem cell transplant, and others. The regional segmentation includes Latin America, Asia-Pacific, the Middle East and Africa, Europe, and North America.
The region of North America holds the maximum market share owing to the presence of key market players in the region along with the highly advanced healthcare system among other developed countries across the globe. The market in this region has also shown prominent growth as a result of improved healthcare facilities, increasing demand for tailored treatments, significant investment in pipeline drug production, and increased public awareness. Due to growth factors such as developing savings, rising disposable incomes, increasing cancer consciousness, and developing healthcare infrastructure, the region of Asia Pacific is also projected to be the fastest-growing region over the forecast period. Furthermore, a growing preference for therapies such as selective therapies with low collateral risk and higher effectiveness is expected to drive demand for the industry in this region in the coming years.
The major players dominating the global acute myeloid leukemia (AML) therapeutics market in terms of revenue and development are Ambit Biosciences Corporation, Genzyme Corporation, Celgene Corporation, Sunesis Pharmaceuticals Inc., Cephalon Inc., Abbvie Inc., Clavis Pharma ASA, Astellas Pharma Inc, Eisai Co. Ltd, and CTI Biopharma Corp. These key players in order to obtain a reputed position in the global market have implemented several strategies such as signing agreements, bonds, contracts, partnerships, joint ventures, new product launches, collaborations, and mergers & acquisitions.
Acute Myeloid Leukemia (AML) Therapeutics
Acute Myeloid Leukemia (AML) Therapeutics